According to the Zhitong Finance App, Wei Jun Biotechnology (00660) announced the results for the year ended June 30, 2023. The group achieved revenue of HK$774 million; loss attributable to company owners was HK$154.33 million; loss per share was HK$9.1 million.
The Group achieved gross profit of approximately HK$50.41 million (18-month period ending June 30, 2022: approximately HK$90.19 million) and gross margin of about 6.52% (18-month period ending June 30, 2022:8.95%) this year. The decline in gross margin was mainly due to the subsequent rise in raw material procurement prices with the relaxation of COVID-19 prevention and control measures in mainland China in 2019, leading to an increase in production costs for the second half of June 30, 2023.